Low molecular weight heparin monotherapy for recurrent abortion with antiphospholipid system: A protocol of a systematic review

Medicine
Lei NiZi-Wei Zhu

Abstract

Previous clinical studies reported low molecular weight heparin (LMWH) monotherpay has been utilized for the treatment of recurrent abortion (RCA) with antiphospholipid system (APS). However, its efficacy is still inconclusive. This systematic review aims to assess its efficacy and safety for patients with RCA and APS. A systematic literature search for article up to February 2019 will be conducted in 9 databases: Cochrane Library, EMBASE, MEDILINE, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data. Inclusion criteria are randomized control trials of LMWH monotherpay for patients with RCA and APS. The Cochrane risk of bias tool will be used to evaluate the methodological quality for each qualified study. The summary results will be showed by using fixed-effects and random-effects models for pooling the data based on the heterogeneity of included studies. This systematic review will assess the clinical efficacy and safety of LMWH monotherpay in treating RCA with APS. The primary outcome is pregnancy loss. The secondary outcomes include frequency of preterm delivery...Continue Reading

References

May 27, 2010·Obstetrics and Gynecology·Panayiotis D ZiakasMichael Voulgarelis
Aug 7, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Andrew SmythVesna D Garovic
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Jan 4, 2015·BMJ : British Medical Journal·Larissa ShamseerUNKNOWN PRISMA-P Group
Oct 13, 2017·American Journal of Reproductive Immunology : AJRI·Shi Hua BaoWei Yan Tu
Jan 13, 2018·Nature Reviews. Disease Primers·Karen SchreiberBeverley J Hunt
Jan 26, 2018·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Kenji Oku
Jan 26, 2018·Nature Reviews. Disease Primers·Karen SchreiberBeverley J Hunt
May 24, 2018·The New England Journal of Medicine·David Garcia, Doruk Erkan
Jul 15, 2018·Thrombosis Research·Vittorio Pengo, Gentian Denas
Aug 18, 2018·Autoimmunity Reviews·Sara De CarolisAntonio Lanzone
Oct 27, 2018·Lupus Science & Medicine·Aleksandra AntovicElisabet Svenungsson
Nov 20, 2018·Lupus·M Kemp, W Thomas

❮ Previous
Next ❯

Citations

Apr 16, 2019·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Yangming LiuHongbo Qi
Jun 30, 2021·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Yan DongXietong Wang

❮ Previous
Next ❯

Software Mentioned

RevMan
Cochrane Handbook for Systematic Reviews of Interventions

Related Concepts

Related Feeds

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.